Influence of systemic and intraperitoneal hyperthermic perfusion chemotherapy on serum VEGF and HE4 in patients with ovarian cancer
10.3760/cma.j.issn.1008-6706.2014.02.011
- VernacularTitle:全身和腹腔热灌注化疗对卵巢癌患者血清血管内皮生长因子和人附睾蛋白4水平的影响
- Author:
Lingling ZHANG
;
Lili HAN
;
Shuzhen LI
- Publication Type:Journal Article
- Keywords:
Ovarian cancer;
Chemotherapy;
Vascular endothelial growth factor;
Human epididymis protein 4
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(2):183-185
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the influence of systemic and intraperitoneal hyperthermic perfusion chemotherapy on serum vascular endothelial growth factor(VEGF) and human epididymis protein 4 (HE4) in patients with ovarian cancer.Methods 116 cases with ovarian cancer were,randomly divided into the observation group and the control group according to the number table,58 cases in each group.The observation group was given systemic and intraperitoneal hyperthermic perfusion chemotherapy,and the control group received systemic chemotherapy,they all completed a total of two cycles of chemotherapy.Serum VEGF and HE4 were measured before and after chemotherapy.Results The total effective rate of the observation group was 74.1％,and that was 56.9％ of the control group,the difference was significant (x2 =4.290,P ＜ 0.05).After chemotherapy,the serum VEGF and HE4 were signifi cantly decreased in two groups,and compared with the control group,the observation group decreased more significantly(t =3.180,2.725,all P ＜ 0.05).Conclusion Systemic and intraperitoneal hyperthermic perfusion chemotherapy in treatment of patients with ovarian cancer can significantly reduce serum VEGF and HE4.
